Increased dosage of wild-type KRAS protein drives KRAS-mutant lung tumorigenesis and drug resistance
T. Ivanisevic, W. Magits, Y. Ma, P. Zhao, E. Van Boxel, B. Lechat, E. Stites, G. Vande Velde, R. Sewduth, A. Sablina
This study shows that increased wild-type KRAS protein dosage in KRAS-mutant lung cancer drives tumor growth and drug resistance, with vascular changes mediated by mTOR pathway activation.
bioRxiv · Feb 27, 2024 · PreprintCancer Biology